Requirement of nuclear factor κB for smac mimetic-mediated sensitization of pancreatic carcinoma cells for gemcitabine-induced apoptosis

Neoplasia

Volumn 13, Issue 12, 2011, Pages 1162-1170

  Stadel, Dominic ^a   Cristofanon, Silvia ^b   Abhari, Behnaz Ahangarian ^b   Deshayes, Kurt ^c   Zobel, Kerry ^c   Vucic, Domagoj ^c   Debatin, Klaus Michael ^a   Fulda, Simone ^a,b  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BV 6; CASPASE 3; CASPASE 8; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL VIABILITY; CHEMOSENSITIZATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVATION; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

EID: 84855440150     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.11460     Document Type: Article

References (28)

1. Li D, Xie K, Wolff R, and Abbruzzese JL (2004). Pancreatic cancer. Lancet 363, 1049-1057.
2. Fulda S (2009). Apoptosis pathways and their therapeutic exploitation in pancreatic cancer. J Cell Mol Med 13, 1221-1227.
3. Fulda S and Debatin KM (2006). Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25, 4798-4811.
4. Ashkenazi A (2008). Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev 19, 325-331.
5. Kroemer G, Galluzzi L, and Brenner C (2007). Mitochondrial membrane permeabilization in cell death. Physiol Rev 87, 99-163.
6. LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, and Korneluk RG (2008). IAP-targeted therapies for cancer. Oncogene 27, 6252-6275.
7. Bertrand MJ, Milutinovic S, Dickson KM, Ho WC, Boudreault A, Durkin J, Gillard JW, Jaquith JB, Morris SJ, and Barker PA (2008). cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 30, 689-700.
8. Varfolomeev E, Goncharov T, Fedorova AV, Dynek JN, Zobel K, Deshayes K, Fairbrother WJ, and Vucic D (2008). c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor α (TNFα)-induced NF-κB activation. J Biol Chem 283, 24295-24299.
9. Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, Benetatos CA, Chunduru SK, Condon SM, McKinlay M, et al. (2007). IAP antagonists target cIAP1 to induce TNFα-dependent apoptosis. Cell 131, 682-693.
10. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P, Zobel K, Dynek JN, Elliott LO, Wallweber HJ, et al. (2007). IAP antagonists induce autoubiquitination of c-IAPs, NF-κB activation, and TNFα-dependent apoptosis. Cell 131, 669-681.
11. Petersen SL, Wang L, Yalcin-Chin A, Li L, Peyton M, Minna J, Harran P, and Wang X (2007). Autocrine TNFα signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 12, 445-456.
12. Baud V and Karin M (2009). Is NF-κB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8, 33-40.
13. Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M, Bhanot U, Hasel C, Moller P, Gschwend JE, et al. (2009). Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res 69, 2425-2434.
14. Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M, Gschwend JE, Simmet T, Debatin KM, and Fulda S (2008). Targeting XIAP bypasses Bcl-2- mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. Cancer Res 68, 7956-7965.
15. Vogler M, Durr K, Jovanovic M, Debatin KM, and Fulda S (2007). Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells. Oncogene 26, 248-257.
16. Fulda S, Friesen C, Los M, Scaffidi C, Mier W, Benedict M, Nunez G, Krammer PH, Peter ME, and Debatin KM (1997). Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res 57, 4956-4964.
17. Karl S, Pritschow Y, Volcic M, Hacker S, Baumann B, Wiesmuller L, Debatin KM, Fulda S (2009). Identification of a novel pro-apopotic function of NF-κB in the DNA damage response. J Cell Mol Med 13, 4239-4256.
18. Kasperczyk H, La Ferla-Bruhl K, Westhoff MA, Behrend L, Zwacka RM, Debatin K-M, and Fulda S (2005). Betulinic acid as new activator of NF-κB: molecular mechanisms and implications for cancer therapy. Oncogene 24, 6945-6956.
19. Wang L, Du F, and Wang X (2008). TNF-α induces two distinct caspase-8 activation pathways. Cell 133, 693-703.
20. Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N, Cuny GD, Mitchison TJ, Moskowitz MA, and Yuan J (2005). Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 1, 112-119.
21. Stadel D, Mohr A, Ref C, MacFarlane M, Zhou S, Humphreys R, Bachem M, Cohen G, Moller P, Zwacka RM, et al. (2010). TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors. Clin Cancer Res 16, 5734-5749.
22. Greten FR, Weber CK, Greten TF, Schneider G, Wagner M, Adler G, and Schmid RM (2002). Stat3 and NF-κB activation prevents apoptosis in pancreatic carcinogenesis. Gastroenterology 123, 2052-2063.
23. Arlt A, Gehrz A, Muerkoster S, Vorndamm J, Kruse ML, Folsch UR, and Schafer H (2003). Role of NF-κB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 22, 3243-3251.
24. Bai L, Chen W, Wang X, Tang H, and Lin Y (2009). IKKβ-mediated nuclear factor-κB activation attenuates Smac mimetic-induced apoptosis in cancer cells. Mol Cancer Ther 8, 1636-1645.
25. Petersen AM, Jung WS, Yang JS, and Stanley HE (2011). Quantitative and empirical demonstration of the Matthew effect in a study of career longevity. Proc Natl Acad Sci USA 108, 18-23.
26. Dineen SP, Roland CL, Greer R, Carbon JG, Toombs JE, Gupta P, Bardeesy N, Sun H, Williams N, Minna JD, et al. (2010). Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer. Cancer Res 70, 2852-2861.
27. Probst BL, Liu L, Ramesh V, Li L, Sun H, Minna JD, and Wang L (2010). Smac mimetics increase cancer cell response to chemotherapeutics in a TNF-α- dependent manner. Cell Death Differ 17, 1645-1654.
28. Fulda S (2009). Inhibitor of apoptosis proteins in hematological malignancies. Leukemia 23, 467-476.